Tharimmune Announces Results In Phase 1 Clinical Trial Of TH104, Compared Oral Transmucosal Delivery Of TH104 To Injectable Reference Approved Drug Completed
Tharimmune Announces Results In Phase 1 Clinical Trial Of TH104, Compared Oral Transmucosal Delivery Of TH104 To Injectable Reference Approved Drug Completed
Tharimmune 公布了 TH104 的 1 期临床试验结果，将 TH104 的口服经粘膜给药与已完成的可注射参考药物进行了比较
Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studies
TH104 具有良好的安全性/耐受性，表现出可自我消退、轻微的副作用特征，与先前的研究一致
Phase 1 clinical trial compared oral transmucosal delivery of TH104 to injectable reference approved drug completed
已完成的 1 期临床试验比较了口服经粘膜给药 TH104 与可注射的参考药物
Company fully funded into 2025 with Phase 2 moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC) study on-track and expected to initiate in 2024
公司在 2025 年获得全额资助，原发性胆源性胆管炎 (PBC) 第 2 期中度至重度慢性瘙痒研究已步入正轨，预计将于 2024 年启动
BRIDGEWATER, NJ / ACCESSWIRE / February 20, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology announced today the completion of the Company's Phase 1 clinical trial with TH104. TH104 is a proprietary transmucosal buccal film...
新泽西州布里奇沃特/ACCESSWIRE/2024年2月20日/Tharimmune, I...
登录免费看全文
登录/注册